Anti-Angiogenic Therapy: Current Challenges and Future Perspectives
Open accessThe DOI matches its Crossref record; 242 of the 246 references it cites were found in a registry or an index.
Abstract
Anti-angiogenic therapy is an old method to fight cancer that aims to abolish the nutrient and oxygen supply to the tumor cells through the decrease of the vascular network and the avoidance of new blood vessels formation. Most of the anti-angiogenic agents approved for cancer treatment rely on targeting vascular endothelial growth factor (VEGF) actions, as VEGF signaling is considered the main angiogenesis promotor. In addition to the control of angiogenesis, these drugs can potentiate immune therapy as VEGF also exhibits immunosuppressive functions. Despite the mechanistic rational that strongly supports the benefit of drugs to stop cancer progression, they revealed to be insufficient in most cases. We hypothesize that the rehabilitation of old drugs that interfere with mechanisms of angiogenesis related to tumor microenvironment might represent a promising strategy. In this review, we deepened research on the molecular mechanisms underlying anti-angiogenic strategies and their failure and went further into the alternative mechanisms that impact angiogenesis. We concluded that the combinatory targeting of alternative effectors of angiogenic pathways might be a putative solution for anti-angiogenic therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tyrosine kinase inhibitors (TKIs) have broadened the scope of anti-angiogenic therapy to include other pro-angiogenic growth factors and receptors such as PDGFR, FGFR, c-MET, and PIGF, which are now mainstay targets of the targeted therapy arsenal (Table 2) [33].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [33]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Park, S. Y., Kang, J. H., Jeong, K. J., Lee, J., Han, J. W., Choi, W. S., Kim, Y. K., Kang, J., Park, C. G., & Lee, H. Y. (2011) · International Journal of Cancer · doi:10.1002/ijc.25589 · Cited by 135
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467 · cited 2×
“The blockage of the VEGF:VEGFR axis seems to be ineffective as monotherapy, and primary or de novo resistance is a common feature in cancer patients [23,123].”
BackgroundCancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · cited 1×
“These strategies have focused mainly on eye disease [110] and wound healing [111], but their application in cancer therapy is under debate [112,113].”
BackgroundAtezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733 · cited 1×
“on tumor growth and an increase in OS [161].”
BackgroundVascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605 · cited 1×
“Moreover, the design and development of new anti-VEGF signaling drugs continues, including the arylamide-5-anilinoquinazoline-8nitro derivative a recent inhibitor of VEGFR2-kinase activity with in vitro anti-tumor and anti-angiogenic activity [38].”
BackgroundFundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Research works printed but not linked: 1
- 5. Domingues, G.; Fernandes, S.G.; Serpa, J. Dynamics of VEGF-A and its Receptors in Cancer Vascularization-An Overview. In Understand Cancer: Research and Treatment ; iConcept Press: Hong Kong, China, Chapter 3; 2015; ISBN 978-1-922227-386.
Cited by
Items 401–428 of 428
Karmakar, S., Moulik, S., Ghosh, S., Uttam, G., Alsharidah, A., Choudhary, R. K., & Rizvi, M. R. (2026) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-026-01148-6
“Most clinically advanced small-molecule anti-angiogenic agents act downstream by inhibiting receptor tyrosine kinases such as VEGFR, PDGFR, and FGFR, often with multi-target profiles that broaden pathway coverage and partly buffer compensatory signalling [2, 12].”
Emerging roles of Notch signaling in the tumor microenvironment of digestive system cancers
Shi, Q., Yang, S., Fu, L., & Chen, X. F. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2026.1840769 · Cited by 2
Flavonoids with anti-angiogenic potential in cancer
Kashyap, D., Sharma, R., Munda, V. S., Garg, V. K., Thakur, S., Sharma, D., Okpala, C. O. R., & Dhiman, V. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-42855-5.00007-8
Metabolic Symbiosis Between Cancer Cells and Endothelial Cells: A Key Driver of Tumor Angiogenesis
Serpa, J. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-12166-0_6
Self-citationNie, W., Luan, T., Liu, C., Sun, G., Qiao, L., Liu, X. R., Cui, W., Liu, H., Xie, J., Zou, X., et al. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124435
Qin, Q., Liu, C., Lu, J., Wang, J., & Li, Z. (2026) · International Journal of Radiation Research · doi:10.66224/ijrr.24.2.10
“Targeted therapy such as anti - angiogenesis and immune checkpoint inhibitors are new ideas for the treatment of CC (14, 15) .”
Biancardi, M. R., Soares, M. Q. S., Caldas, R. J., Honório, H. M., Santos, P. S. D. S., & Rubira‐Bullen, I. R. F. (2026) · Revista de Odontologia da UNESP · doi:10.1590/1807-2577.20250026
Götz, L. S., Deo, A., Scherer, S. D., D’Antonio, L., Weber, H. T., Sedlmeier, G., Flores, L. P. T., Kaiser, U., Far, E., Raviv, Z., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.05.742008
“This dual mechanism is particularly attractive given that resistance to conventional anti-angiogenic therapies frequently arises from compensatory pathways and tumor heterogeneity [39-40].”
Wang, X., You, R., Fang, W., Kang, L., Cai, D., Hou, D., Liu, J., Zhang, S., & Huang, H. (2026) · Functional & Integrative Genomics · doi:10.1007/s10142-026-02003-x
“This observation accounts for the therapeutic limitations of VEGF-pathway inhibitors in AML (Bergers and Hanahan 2008; Lopes-Coelho et al. 2021) and argues for combined suppression of both canonical angiogenesis and exosome-driven vascular remodeling.”
Lysosomal channel TPC2 modulates microglia-endothelial signaling in choroidal angiogenesis
Lu, Y., Reschigna, A., Kynast, F., Yang, Z., Gerhardt, M., Kielkowski, P., Priglinger, S., Biel, M., & Michalakis, S. (2026) · Angiogenesis · doi:10.1007/s10456-026-10082-4
Ferreira, I. G., Oliveira, I. S., Cresswell, C. T., Raybould, C. O., Horder, J. L., Harris, P. E., Arantes, E. C., & Benest, A. V. (2026) · Biochimie · doi:10.1016/j.biochi.2026.08.011
Trusov, P. V., Zaitseva, N. V., & Chigvintsev, V. М. (2026) · Mathematical Biology and Bioinformatics · doi:10.17537/2026.21.332
Biosimilars and biologics in cervical cancer
Sanapalli, V., Palit, S., Gundrathi, S. G., Deshpande, A., Swaroop, A. K., Patil, P., & Sanapalli, B. K. R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-43824-0.00015-8
El-brolsy, H. M. E. M., El‐Borady, O. M., El-Kemary, M. A., & Hanafy, N. A. N. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108867
Tumor resistance to protein kinase inhibitors
Sengar, M. S., Paliwal, A., Kaushik, N., Singh, S., Kashyap, P., Paliwal, D., & Negi, S. (2026) · Journal of Chemotherapy · doi:10.1080/1120009x.2026.2728432
Tang, D., Li, Q., Tacchi, C., Banchi, M., & Bocci, G. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189713
Zhang, D., Rong, C. H. E. N., & Zhang, D. (2026) · Scientia Sinica Vitae · doi:10.1360/ssv-2026-0197
Yang, X., Wang, Y., Qiaolongbatu, X., Qu, H., Li, Z., Wu, J., & Wu, Z. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05872-y
Endothelial plasticity as a continuum in the tumor microenvironment
Rathod, G., Parmar, P. B., & Teja, A. A. (2026) · Vascular Biology · doi:10.1530/vb-26-0007
“…3 (PFKFB3), which regulates glycolysis, and carnitine palmitoyltransferase 1A (CPT1A), a key mediator of fatty acid oxidation, reflect the bioenergetic adaptations that support endothelial proliferation and survival in the tumor microenvironment (30, 31).”
Li, Z., Liang, Y., Chen, L., Cai, M., & Wu, H. (2026) · Biomaterials Advances · doi:10.1016/j.bioadv.2026.215198
Li, Y., Xu, L., Yin, C., & Wang, F. (2026) · International Journal of Clinical Practice · doi:10.1155/ijcp/1390370
Emara, H. M., & Allam, N. K. (2026) · RSC Medicinal Chemistry · doi:10.1039/d6md00590j
Zhang, T., Zhang, C., Wang, C., Sun, M., Wei, J., Yu, J., Sui, L., & Ma, W. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218908
Zhu, X., Wei, T., Yuan, G., Shen, Y., Li, Y., Ning, J., Guo, F., & Chen, K. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.103069
“…our findings suggest that SATB2 contributes to reduced sensitivity to anti-angiogenic therapy through reinforcement of HIF-1 α -dependent transcriptional programs, consistent with evidence that hypoxia-related adaptive and compensatory mechanisms can limit responses to VEGF-directed therapy [27].”
Liu, Z., Cui, Z., Zhang, X., Wang, R., Dai, X., & Shi, L. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119457
Targeting angiogenesis: vascular endothelial growth factor and its inhibitors
Attri, R., Singh, R., Saha, R., Kumar, S., Porwal, O., & Kumar, B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-49074-3.00002-9
Liu, Z., Zhong, J., Wan, R., Duan, J., Wang, Z., Bai, H., & Wang, J. (2026) · Cancers · doi:10.3390/cancers18213541
Metadata
- Authors
- Lopes-Coelho, F., Martins, F., Pereira, S. A., & Serpa, J.
- Affiliations
- Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Prof. Lima Basto, 1099-023 Lisboa, Portugal
- Instituto Português de Oncologia Francisco Gentil (PT)
- Universidade Nova de Lisboa (PT)
- Corresponding author
- Serpa, Jacinta
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-04-05
- Volume
- 22
- Issue
- 7
- Pages
- 3765
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8038573
- OpenAlex
- W3140967360
- Cited by
- 416
- References
- 246
- Citations by year
- 2026: 61 · 2025: 98 · 2024: 117 · 2023: 86 · 2022: 46 · 2021: 8
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministério da Educação e Ciência
- Ministério da Ciência, Tecnologia e Ensino Superior
- Ministério da Educação
- Fundação para a Ciência e a Tecnologia (/2017, iNOVA4Health, PD/BD/128337/2017)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- anti-angiogenic therapy, angiogenesis, VEGF signaling, tumor microenvironment, cancer immunotherapy, immunosuppression, drug repurposing, combination therapy, tumor vasculature, treatment resistance
- MeSH terms
- Animals, Humans, Neoplasm Proteins, Neoplasms, Neovascularization, Pathologic, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.